AbbVie, Besins must pay $448 million in FTC AndroGel case, judge rules

Washington, D.C. ( July 3, 2018) -- AbbVie and Besins Healthcare violated antitrust law by filing sham patent litigation to delay the availability of generic AndroGel, a Philadelphia federal judge ruled Friday, ordering the companies to pay $448 million in disgorgement....

Related Sections

FTCWatch

MLex
1101 17th Street, NW, Suite 1003
Washington, DC 20036

Email: customerservices@ftcwatch.com
Phone: (800) 356-6547

(Monday-Friday, 9 AM to 6 PM EST)

May not be reproduced in any form, including electronic retransmission.
Have a news tip for FTCWatch? Send an e-mail to tips@ftcwatch.com.

Connect with us:

Already have access? Click here to login

Get instant access to the one-stop news source for business lawyers

Register for a complimentary 14-day trial with access to all sections and newsletters.

Email (NOTE: Free email domains not supported)

First Name

Last Name

Job Title

Postal code*

PLEASE NOTE: A verification email will be sent to your address before you can access your trial.

Password (at least 8 characters required)

Confirm Password

Phone Number (###-###-####)

Select at least one primary interest:

FTCWatch

FTCWatch may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.

You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.

We take your privacy seriously. Please see our Privacy Policy.

Start Reading

Already have access?

Email:
Password: Forgot your password?
Remember login
Sign In

Sign up for our FTCWatch newsletter

You must correct or enter the following before you can sign up:

Please provide a professional email:

Select more newsletters to receive for free

FTCWatch

FTCWatch takes your privacy seriously. Please see our Privacy Policy.